Study [Ref.] | Intervention | Total participants | Participants | ||
MI | CV death | Overall mortality | |||
Aaron 15# | Salmeterol/fluticasone combination | 145 | 1 | 0 | 6 |
Salmeterol xinafoate | 148 | 2 | 1 | 6 | |
Placebo | 156 | 2 | 1 | 4 | |
Burge 16¶ | Fluticasone propionate | 376 | 8 | 10 | 32 |
Placebo | 375 | 9 | 12 | 36 | |
Calverley 17¶ | Salmeterol/fluticasone combination | 358 | 3 | 0 | 2 |
Salmeterol xinafoate | 372 | 2 | 0 | 3 | |
Fluticasone propionate | 374 | 1 | 1 | 3 | |
Placebo | 361 | 1 | 3 | 7 | |
Calverley 19 | Formoterol/budesonide | 254 | NA | NA | 5 |
Formoterol | 255 | NA | NA | 13 | |
Budesonide | 257 | NA | NA | 6 | |
Placebo | 256 | NA | NA | 5 | |
Calverley 18¶,+ | Salmeterol/fluticasone combination | 1546 | 28 | 60 | 193 |
Salmeterol xinafoate | 1542 | 36 | 45 | 205 | |
Fluticasone propionate | 1552 | 30 | 61 | 246 | |
Placebo | 1544 | 28 | 71 | 231 | |
Ferguson 20¶ | Salmeterol/fluticasone combination | 394 | 2 | 2 | 6 |
Salmeterol xinafoate | 388 | 3 | 1 | 3 | |
FLTA3025 21¶ | Fluticasone propionate | 434 | 1 | 0 | 0 |
Placebo | 206 | 1 | 0 | 0 | |
Hanania 26¶ | Salmeterol/fluticasone combination | 178 | 0 | 0 | 0 |
Salmeterol xinafoate | 177 | 0 | 0 | 0 | |
Fluticasone propionate | 183 | 1 | 0 | 0 | |
Placebo | 185 | 0 | 0 | 0 | |
Kardos 27¶ | Salmeterol/fluticasone combination | 507 | 3 | 1 | 7 |
Salmeterol xinafoate | 487 | 2 | 3 | 9 | |
Lung Health Study 29 | Triamcinolone | 559 | NA | 6 | 15 |
Placebo | 557 | NA | 2 | 19 | |
Lofdahl 28 | Budesonide | 634 | 9 | 2 | 8 |
Placebo | 643 | 14 | 1 | 10 | |
Mahler 30¶ | Salmeterol/fluticasone combination | 165 | 0 | 0 | 0 |
Salmeterol xinafoate | 160 | 0 | 0 | 0 | |
Fluticasone propionate | 168 | 0 | 0 | 0 | |
Placebo | 181 | 0 | 0 | 3 | |
Paggiaro 31¶ | Fluticasone propionate | 142 | 1 | 0 | 0 |
Placebo | 139 | 1 | 0 | 2 | |
Rennard 32 | Budesonide/formoterol | 988 | 5 | NA | 9 |
Formeterol | 495 | 2 | NA | 2 | |
Placebo | 481 | 1 | NA | 4 | |
SCO100250 22¶ | Salmeterol/fluticasone combination | 394 | 2 | 0 | 4 |
Salmeterol xinafoate | 403 | 1 | 0 | 6 | |
SCO100470 24¶ | Salmeterol/fluticasone combination | 518 | 0 | 0 | 3 |
Salmeterol xinafoate | 532 | 1 | 2 | 3 | |
SCO40041 23¶ | Salmeterol/fluticasone combination | 92 | 5 | 0 | 5 |
Salmeterol xinafoate | 94 | 0 | 1 | 7 | |
SFCT01/SCO30002 25¶ | Fluticasone propionate | 131 | 1 | 0 | 0 |
Placebo | 125 | 0 | 0 | 0 | |
Szafranski 33 | Formoterol/budesonide | 208 | NA | NA | 6 |
Formoterol | 201 | NA | NA | 6 | |
Budesonide | 198 | NA | NA | 5 | |
Placebo | 205 | NA | NA | 9 | |
Tashkin 34 | Budesonide/formoterol | 845 | 1 | 1 | 7 |
Formoterol | 284 | 1 | 1 | 1 | |
Budesonide | 275 | 1 | 1 | 2 | |
Placebo | 300 | 0 | 0 | 1 | |
van der Valk 35¶ | Fluticasone propionate | 123 | 0 | 1 | 4 |
Placebo | 121 | 0 | 0 | 0 | |
Vestbo 36 | Budesonide | 145 | 2 | 3 | 4 |
Placebo | 145 | 2 | 0 | 5 | |
Wouters 37¶ | Salmeterol/fluticasone combination | 189 | 0 | 0 | 2 |
Salmeterol xinafoate | 184 | 1 | 2 | 4 |
Data are presented as n. MI: myocardial infarction; NA: not available. #: reported as serious adverse event of MI or acute arrhythmia; ¶: CV adverse event data extracted from manufacturers clinical trials register; +; CV mortality data extracted from regulatory agencies as unavailable in publications.